Skip to content

AcuCort expands its commercialization team and hires Project Manager

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces that the company has recruited James Kereki as Project Manager. AcuCort’s approved drug ISICORT®/Zeqmelit is approaching market introduction and James will focus on leading projects effectively through the commercialization process. He has solid experience from the commercialization of new products, both in Sweden and internationally, gained from his previous roles in the pharma industry.

James Kereki has broad experience of international product launches as well as marketing and sales work within the life science industry from, among other things, Oticon Medical AB, Orion Pharma AB, Desitin Pharma AB and Allergan. In the new Project Manager role at AcuCort, he is responsible for leading prioritized projects effectively through the commercialization process. AcuCort’s overarching goal is to commercialize ISICORT®/Zeqmelit globally, i.e. in the EU, the US and in selected key markets.

”It is very gratifying that we now have James Kereki on board as Project Manager. He has many years of experience in commercializing pharmaceutical products. In addition, he has solid experience from interacting with decision-makers in our therapy areas as well as extensive knowledge in the area of marketing and sales work of pharmaceuticals. James is most welcome to our team. I look forward to an intense and exciting fall and a continued positive development of AcuCort,” says Jonas Jönmark, CEO of AcuCort AB.

In the development of the drug ISICORT®/Zeqmelit, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick accessibility and relief in acute situations such as severe and acute allergic reactions. The drug was recently approved in Denmark under the name Zeqmelit and has previously been approved in Sweden under the brand name ISICORT®.

The information was submitted for publication, through the agency of the contact person below, on August 30, 2022.

For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400

About AcuCort AB (publ)
AcuCort has developed and commercializes ISICORT®/Zeqmelit, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. The product is approved in Sweden and Denmark. Altogether, this strengthens the company’s assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit